mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer

mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer is a phase 2, randomised interventional study registered as NCT06890624 by Sun Yat-sen University, with a registry enrolment figure of 138 participants, started 2026-10-01 and due to reach its primary completion in 2029-10-01. Interventions recorded: cmFOLFOXIRI plus PD-1 inhibitor; mFOLFOX6. Conditions listed: Colon Cancer (Stage II &Amp;Amp; III). Primary outcome: Pathologic complete response rate. Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the colon (≥ 12 cm from the anal verge)". No results are recorded here; the registry entry is the source.